Olympus Partners with Endocision to Launch Revolutionary Cryobiopsy System

In an exciting announcement from the medical technology sector, Olympus Corporation has entered into a global distribution agreement with Endocision for a pioneering portable cryobiopsy system designed for respiratory care. This substantial agreement underscores Olympus's commitment to advancing endoscopy-enabled medical solutions on a global scale.

A Leap Forward in Respiratory Medicine

The newly introduced portable and single-use flexible cryocatheter system serves multiple clinical purposes, facilitating various diagnostic and therapeutic bronchoscopic procedures. This innovative device is expected to enhance the Olympus product portfolio in respiratory medicine, which already includes advanced tools such as endobronchial ultrasound (EBUS). The EBUS technology is crucial for visualizing and obtaining biopsies of lung tissue and lymph nodes, marking a significant enhancement in patient care.

Seiji Kuramoto, Executive Officer and head of the Surgical and Interventional Solutions division at Olympus, emphasized that this partnership merges Olympus's ultrasound technology expertise with Endocision's innovative cryotechnology, ultimately aiming for better patient outcomes.

Prioritizing Portability and Versatility

One of the key features of the cryocatheter system is its portability. The design does not require a power source or large CO₂ cylinders, which makes it versatile for use in a variety of hospital settings, including bronchoscopy suites, intensive care units, operating rooms, and emergency departments. Given the rise of cryotechnology as a vital tool in interventional pulmonology and thoracic endoscopy, this system represents a significant advancement, supporting both tissue sampling and therapeutic interventions within the airways.

Clinical applications of the system include transbronchial cryobiopsy for tissue sampling, cryoextraction of foreign bodies, blood clots, and mucus plugs, along with endobronchial tumor resections and airways recanalization procedures. A crucial aspect noted in recent studies indicates that cryobiopsies may provide larger tissue samples compared to conventional forceps biopsies, minimizing compression-related tissue damage which can potentially improve histopathological and molecular analyses.

Collaboration with Endocision

Dr. Moishe Liberman, President and Chief Medical Officer of Endocision, expressed enthusiasm about unveiling the next generation of cryocatheter systems in partnership with Olympus for advancing interventional pulmonology and thoracic endoscopy. He highlighted that the Endocision cryocatheter system is crafted to support a broad range of bronchoscopy applications, ensuring the usability of cryotechnology in diverse clinical settings.

The flexible cryocatheter system will be presented at the upcoming Annual Congress of the American Association for Bronchology and Interventional Pulmonology (AABIP) from August 20 to 22 in Denver. This showcase illustrates the collaborative spirit of Olympus and Endocision's efforts to push the boundaries of medical technology for enhanced respiratory care.

Commitment to Health Innovation

As a global leader in medical technology, Olympus has long been dedicated to the mission of making people's lives healthier, safer, and more fulfilling. With partnerships like the one with Endocision, Olympus leverages its capabilities in developing innovative solutions aimed at earlier diagnosis, treatment, and minimal invasiveness to improve patient outcomes.

For more than a century, Olympus has been focused on contributing to society by delivering products that promise optimal results for customers worldwide. Further information regarding Olympus’s offerings can be found on their official website and through their LinkedIn profile.

About Endocision

Founded in 2019, Endocision is a Canadian medical technology company committed to developing innovative minimally invasive cryotherapy devices for diagnosing and treating lung diseases. By creating technologies compatible with both conventional and robotic bronchoscopy platforms, Endocision aims to enhance treatment outcomes for patients through safer and more effective lung interventions. More details are available on their website and LinkedIn profile.

Conclusion

This groundbreaking collaboration between Olympus and Endocision represents an integral step forward in the medical field, especially concerning respiratory procedures. The introduction of this cryobiopsy system is set to transform standard practices, ultimately enhancing recovery outcomes for patients across various healthcare environments.